255 related articles for article (PubMed ID: 25003090)
1. Current status of human papillomavirus vaccines.
Kim KS; Park SA; Ko KN; Yi S; Cho YJ
Clin Exp Vaccine Res; 2014 Jul; 3(2):168-75. PubMed ID: 25003090
[TBL] [Abstract][Full Text] [Related]
2. Human papilloma virus in oral cancer.
Kim SM
J Korean Assoc Oral Maxillofac Surg; 2016 Dec; 42(6):327-336. PubMed ID: 28053902
[TBL] [Abstract][Full Text] [Related]
3. Ten years of HPV vaccines: State of art and controversies.
Angioli R; Lopez S; Aloisi A; Terranova C; De Cicco C; Scaletta G; Capriglione S; Miranda A; Luvero D; Ricciardi R; Montera R; Plotti F
Crit Rev Oncol Hematol; 2016 Jun; 102():65-72. PubMed ID: 27066937
[TBL] [Abstract][Full Text] [Related]
4. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
5. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
7. [HPV vaccination and the prevention of genital warts and precancerous lesions-current evidence and evaluation].
Osmani V; Klug SJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 May; 64(5):590-599. PubMed ID: 33851224
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
9. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
12. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
15. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
17. A review of clinical trials of human papillomavirus prophylactic vaccines.
Schiller JT; Castellsagué X; Garland SM
Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
[TBL] [Abstract][Full Text] [Related]
18. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
19. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Schiller JT; Castellsagué X; Villa LL; Hildesheim A
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
